Off-label use of atypical antipsychotics in personality disorders

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 11, 2012, Pages 1575-1585

  Rosenbluth, Michael ^a   Sinyor, Mark ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atypical antipsychotics; Borderline personality disorder; Off label; Personality disorders

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLONIDINE; CLOZAPINE; FLUOXETINE; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LOXAPINE; METHYLPHENIDATE; NALOXONE; NALTREXONE; OLANZAPINE; OMEGA 3 FATTY ACID; PLACEBO; QUETIAPINE; RISPERIDONE; TIOTIXENE; TOPIRAMATE; TRIFLUOPERAZINE; VALPROIC ACID; ZIPRASIDONE;

ANTISOCIAL BEHAVIOR; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; AVOIDANT PERSONALITY DISORDER; BEHAVIOR DISORDER; BEHAVIOR THERAPY; BORDERLINE STATE; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DISSOCIATIVE DISORDER; DRUG EFFICACY; DSM-5; DSM-IV-TR; DYSTHYMIA; HUMAN; HYPERLIPIDEMIA; IMPULSIVE AGGRESSION; NEUROBIOLOGY; OBSESSIVE COMPULSIVE DISORDER; OFF LABEL DRUG USE; PERSONALITY DISORDER; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOIDISM; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SEDATION; SIDE EFFECT; SUICIDAL IDEATION; SUICIDE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; HUMANS; META-ANALYSIS AS TOPIC; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84863789637     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.608351     Document Type: Review

References (78)

1. American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry 2001;158(10 Suppl):1-52
2. Zanarini MC. Psychotherapy of borderline personality disorder. Acta Psychiatr Scand 2009;120:373-7
3. Zanarini MC. Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep 2004;6:66-70
4. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs 2008;22:671-92
5. Buckley PF. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001;50:912-24
6. Lieb K, Vollm B, Rucker G, et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010;196:4-12
7. Abraham PF, Calabrese JR. Evidenced-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord 2008;111:21-30
8. Grilo CM, McGlashan TH. 'Course and outcome'. In: OLDHAN JM, Skodol AE, Bender D. editors. Essentials of personality disorders. VA American Psychiatric Press; Arlington: 2009. p. 63-85
9. National Institute for Clinical Excellence (NICE). Borderline personality disorder: Treatment and management. Clinical guideline. NICE; London: 2009
10. Nose M, Cipriani A, Biancosino B, et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2006;21:345-53
11. Stoffers J, Vollm BA, Rucker G, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 2010;6:CD005653
12. Bogenschutz MP, Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004;65:104-9
13. Linehan MM, McDavid JD, Brown MZ, et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: A double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69:999-1005
14. Schulz SC, Zanarini MC, Bateman A, et al. Olanzapine for the treatment of borderline personality disorder: Variable dose, 12-week, randomised doubleblind placebo-controlled study. Br J Psychiatry 2008;193:485-92
15. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001;62:849-54
16. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. Am J Psychiatry 2006;163:833-8
17. Pascual JC, Soler J, Puigdemont D, et al. Ziprasidone in the treatment of borderline personality disorder: A double-blind, placebo-controlled, randomized study. J Clin Psychiatry 2008;69:603-8
18. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004;65:903-7
19. Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005;162:1221-4
20. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry 2006;67:1042-6
21. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: Impulsivity as main target. J Clin Psychiatry 2005;66:1298-303
22. Perrella C, Carrus D, Costa E, et al. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:158-63
23. Van Den Eynde F, Senturk V, Naudts K, et al. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol 2008;28:147-55
24. Van Den Eynde F, De Saedeleer S, Naudts K, et al. Quetiapine treatment and improved cognitive functioning in borderline personality disorder. Hum Psychopharmacol 2009;24:646-9
25. Rocca P, Marchiaro L, Cocuzza E, et al. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002;63:241-4
26. Ilardi S, Craighead W. Personality pathology and response to somatic treatments for major depression: A critical review. Depression 1995;2:200-17
27. Sanderson WC, Wetzler S, Beck AT, et al. Prevalence of personality disorders in patients with major depression and dysthymia. Psychiatry Res 1992;42:93-9
28. Brieger P, Ehrt U, Marneros A. Frequency of comorbid personality disorders in bipolar and unipolar affective disorders. Compr Psychiatry 2003;44:28-34
29. Zanarini MC, Frankenburg FR, Hennen J, et al. Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry 2004;161:2108-14
30. Fava M, Farabaugh AH, Sickinger AH, et al. Personality disorders and depression. Psychol Med 2002;32:1049-57
31. Hirschfeld RM, Russell JM, Delgado PL, et al. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 1998;59:669-75
32. Mullen LS, Blanco C, Vaughan SC, et al. Defense mechanisms and personality in depression. Depress Anxiety 1999;10:168-74
33. Skodol AE, Grilo CM, Keyes KM, et al. Relationship of personality disorders to the course of major depressive disorder in a nationally representative sample. Am J Psychiatry 2011;168:257-64
34. Grilo CM, Stout RL, Markowitz JC, et al. Personality disorders predict relapse after remission from an episode of major depressive disorder: A 6-year prospective study. J Clin Psychiatry 2010;71:1629-35
35. Schulz SC, Camlin KL, Berry SA, et al. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999;46:1429-35
36. Kool S, Dekker J, Duijsens IJ, et al. Efficacy of combined therapy and pharmacotherapy for depressed patients with or without personality disorders. Harv Rev Psychiatry 2003;11:133-41
37. Newton-Howes G, Tyrer P. Pharmacotherapy for personality disorders. Expert Opin Pharmacother 2003;4:1643-9
38. Cardish R. J., (2007) Psychopharmacologic management of suicidality in personality disorders. Can. J. Psychiatry. Vol 52 (SUPPL1) 115-275p.
39. Cardish RJ. Psychopharmacologic management of suicidality in personality disorders. Can J Psychiatry 2007;52(Suppl 1):115-27S 39. Black DW, Blum N, Pfohl B, et al. Suicidal behavior in borderline personality disorder: Prevalence, risk factors, prediction, and prevention. J Personal Disord 2004;18:226-39
40. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: A meta-analysis. Schizophr Res 2005;73:139-45
41. Agid O, Foussias G, Singh S, et al. Where to position clozapine: Re-examining the evidence. Can J Psychiatry 2010;55:677-84
42. Nielsen J, Dahm M, Lublin H, et al. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010;24:965-71
43. Benedetti F, Sforzini L, Colombo C, et al. Low dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998;59:103-7
44. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: A preliminary study. Compr Psychiatry 1993;34:402-5
45. Oumaya M, Friedman S, Pham A, et al. Borderline personality disorder, self-mutilation and suicide: Literature review. Encephale 2008;34:452-8
46. Chengappa KN, Ebeling T, Kang JS, et al. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999;60:477-84
47. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998;52:13-19
48. Baldessarini RJ, Tondo L. Lithium and suicidal risk. Bipolar Disord 2008;10:114-15
49. Khalifa N, Duggan C, Stoffers J, et al. Pharmacological interventions for antisocial personality disorder. Cochrane Database Syst Rev 2010;8:CD007667
50. Hirose S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry Clin Neurosci 2001;55:161-2
51. Alex R, Ferriter M, Jones H, et al. Pharmacological interventions for obsessive-compulsive personality disorder (Protocol). Cochrane Database Syst Rev 2010;5 CD008517
52. Farooq S, Vollm BA, Husain N, et al. Pharmacological interventions for schizotypal personality disorder (Protocol). Cochrane Database Syst Rev 2011;3:CD009047
53. Farooq S, Vollm BA, Stoffers J, et al. Pharmacological interventions for schizoid personality disorder (Protocol). Cochrane Database Syst Rev 2011;3:CD009048
54. Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003;64:628-34
55. Skodol AE, Bender DS, Morey LC, et al. Personality disorder types proposed for DSM-5. J Personal Disord 2011;25:136-69
56. Citrome L, Volavka J. The promise of atypical antipsychotics: Fewer side effects mean enhanced compliance and improved functioning. Postgrad Med 2004;116:49-63
57. Aia PG, Revuelta GJ, Cloud LJ, et al. Tardive dyskinesia. Curr Treat Options Neurol 2011;13:231-41
58. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93
59. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs 2007;21:911-36
60. Soloff PH, Meltzer CC, Becker C, et al. Impulsivity and prefrontal hypometabolism in borderline personality disorder. Psychiatry Res 2003;123:153-63
61. Tost H, Alam T, Meyer-Lindenberg A. Dopamine and psychosis: Theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev 2010;34:689-700
62. Gunderson JG. Pharmacotherapy for patients with borderline personality disorder. Arch Gen Psychiatry 1986;43:698-700
63. Links PS, Steiner M. Psychopharmacologic management of patients with borderline personality disorder. Can J Psychiatry 1988;33:355-9
64. Shafti SS, Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder: A randomized double-blind trial. J Clin Psychopharmacol 2010;30:44-7
65. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988;45:111-19
66. Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986;43:680-6
67. Leone N. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982;43:148-50
68. Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders: Meta-analyses of randomized controlled trials. J Clin Psychiatry 2010;71:14-25
69. Mercer D, Douglass AB, Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. J Personal Disord 2009;23:156-74
70. Perugi G, Fornaro M, Akiskal HS. Are atypical depression, borderline personality disorder and bipolar II disorder overlapping manifestations of a common cyclothymic diathesis? World Psychiatry 2011;10:45-51
71. Philipsen A, Schmahl C, Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 2004;37:196-9
72. Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, et al. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: An open-label trial. J Clin Psychiatry 1999;60:598-603
73. Philipsen A, Richter H, Schmahl C, et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry 2004;65:1414-19
74. Golubchik P, Sever J, Zalsman G, et al. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: A preliminary open-label trial. Int Clin Psychopharmacol 2008;23:228-31
75. McClure MM, Barch DM, Romero MJ, et al. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol Psychiatry 2007;61:1157-60
76. Gunderson JG, Weinberg I, Daversa MT, et al. Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. Am J Psychiatry 2006;163:1173-8
77. Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review. Bipolar Disord 2006;8:625-39
78. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995 - 2008. Pharmacoepidemiol Drug Saf 2011;20:177-84